Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
MWN-AI** Summary
Biotricity Inc. (OTCQB: BTCY), a pioneering Technology-as-a-Service (TaaS) provider in the healthcare sector, is set to announce its Fiscal 2026 Third Quarter Financial Results and provide a business update during a call on February 11, 2026, at 4:30 PM EST. The company's continued commitment to driving revenue growth, enhancing operational efficiency, and achieving positive EBITDA reflects its strategic focus on remote monitoring and diagnostic solutions for chronic care management.
The upcoming call will feature remarks from CEO Dr. Waqaas Al-Siddiq and CFO John Ayanoglou, followed by a Q&A session catering to investor inquiries. Biotricity's ongoing progress in its financial performance highlights its success in establishing a strong foothold in the healthcare market. The company aims to bridge gaps in remote monitoring while maintaining high standards in preventive and personal care, making significant strides in enhancing patient outcomes.
Listeners can access the call via a toll-free number or through a webcast, with replays available for later viewing. In this communication, Biotricity emphasizes its innovative technology solutions, exemplified by products like Bioflux, designed to ensure continuous clinical-grade monitoring for patients in home settings.
As Biotricity continues to navigate the evolving healthcare landscape, it remains vigilant about potential challenges that could impact its performance. The company acknowledges that forward-looking statements in the announcement are based on current projections and involve risks, uncertainties, and assumptions that may affect actual results. Stakeholders are encouraged to consider these factors as they assess Biotricity's growth trajectory.
Investors can stay updated on Biotricity’s developments through their corporate website and social media platforms. The forthcoming earnings call is anticipated to shed light on the company’s future directions and market strategies.
MWN-AI** Analysis
As Biotricity Inc. prepares to announce its Fiscal 2026 Third Quarter Financial Results on February 11, market participants should closely monitor several key indicators that could influence the company's stock trajectory in the coming months. With a focus on remote monitoring and chronic care management, Biotricity's ongoing commitment to revenue growth, margin strength, and operational efficiency positions the company favorably within the competitive healthcare technology landscape.
The expectation of continued positive EBITDA signifies that Biotricity is not only generating revenue but also doing so while managing its costs effectively. This growing profitability may attract institutional investors, improving liquidity and potentially increasing market valuation. Attendees of the results call can anticipate insights from Dr. Waqaas Al-Siddiq, the Founder and CEO, along with CFO John Ayanoglou, regarding strategic initiatives that may further bolster expansion or product offerings.
Investors should assess the company's guidance and any forward-looking statements made during the call, as these will provide clues to the sustainability of growth patterns observed. The healthcare sector, increasingly driven by technological advancements and remote patient monitoring, offers substantial opportunities for Biotricity. However, the company must navigate various risks, including regulatory challenges, competition, and the need for additional funding, which could impact future profitability.
In the short term, a bullish sentiment may prevail if the financial results and strategic plans resonate well with investors. However, it’s advisable to remain vigilant regarding market conditions and Biotricity's operational execution. Investors may want to consider establishing or adjusting their positions based on the outcomes of the February 11 call, refining their strategies in response to the information discussed and overall market dynamics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA
REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time. The Company announces continued progress in its financial performance, including achieving a positive EBITDA and continued growth. Biotricity’s Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors.
Event: Biotricity Fiscal 2026 Third Quarter Financial Results and Business Update Call
Date: Wednesday, February 11, 2026
Time: 4:30 PM ET (1:30 PM PT)
Toll Free: 1-877-269-7751
International: 1-201-389-0908
Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1751341&tp_key=10b4deecf5
Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode.
A replay of the call will be available approximately 3 hours after the live call via the Investors section of the Biotricity website at https://biotricity.com/investors/.
Toll Free Replay Number: 1-844-512-2921
International: 1-412-317-6671
Replay Access ID: 13758520
Expiration: Wednesday, February 25, 2026 at 11:59 PM ET
About Biotricity Inc.
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.
To learn more about the benefits of using Biotricity’s solutions, click here and here. For consumers interested in continuous, 24/7 clinical-grade monitoring at home with Bioheart, click here.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contacts:
Investor relations:
Biotricity Investor Relations
Investors@biotricity.com
Media
Website
Facebook
Instagram
LinkedIn
YouTube
FAQ**
Given the continued revenue growth and positive EBITDA, what specific strategies is Biotricity Inc. (BTCY) implementing in Q3 of Fiscal 2026 to enhance operational efficiency and margin strength?
How does Biotricity Inc. (BTCY) plan to sustain its revenue growth in the competitive healthcare market while ensuring that operational efficiency and margin strength are maintained?
Can you provide insights into how Biotricity Inc. (BTCY) measures operational efficiency and how past improvements have influenced recent financial performance?
In the context of achieving positive EBITDA, what are the main challenges Biotricity Inc. (BTCY) faces, and how does the company plan to overcome them in the upcoming quarters?
**MWN-AI FAQ is based on asking OpenAI questions about Biotricity Inc. (OTC: BTCY).
NASDAQ: BTCY
BTCY Trading
-26.67% G/L:
$0.22 Last:
100,246 Volume:
$0.2531 Open:
